Advertisement

Medical Management of Obesity

  • Marianela Aguirre Ackermann
Chapter

Abstract

The genetic-environment combination is central to the genesis of obesity. Obesity emerged as one of the major health problems during the last century, from the enormous environmental changes that the world experienced. Environmental factors favoring a positive energy balance and weight gain include, on the one hand, increased availability of food, particularly high-calorie foods, and increased portion sizes and, on the other hand, decreased movement, with less time of physical activity at work and the replacement of physical activity in leisure time with sedentary activities such as watching TV and the use of electronic devices. Other factors considered to contribute to the obesity epidemic are use of drugs that have weight gain as a side effect, reduction in variability of ambient temperatures, sleep debt, increasing maternal age, greater fecundity among people with higher adiposity, assortative mating, endocrine disruptors, microorganisms, epigenetics, and intrauterine and intergenerational effects. These and many other factors, combined with medical innovations that have reduced mortality and prolonged life, laid the foundation for the obesity epidemic.

Keywords

Obesity Medical management Nonsurgical approach Weight loss management/treatment Lifestyle intervention Behavior therapy Physical activity Pharmacotherapy 

References

  1. 1.
    Popkin BM, Hawkes C. Sweetening of the global diet, particularly beverages: patterns, trends, and policy responses. Lancet Diabetes Endocrinol. 2016;4:174–86.CrossRefPubMedGoogle Scholar
  2. 2.
    Church TS, Thomas DM, Tudor-Locke CT. Trends over 5 decades in U.S. occupation-related physical activity and their associations with obesity. PLoS One. 2011;6(5):e19657.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Mc Allister EJ, Dhurandhar N, Keith S. Ten putative contributors to the obesity epidemic. Crit Rev Food Sci Nutr. 2009;49:868–913.CrossRefGoogle Scholar
  4. 4.
    Allison DB, Downey M, Atkinson RL. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obesity (Silver Spring). 2008;16:1161–77.CrossRefGoogle Scholar
  5. 5.
    Garvey T, Mechanick JI, Brett EM. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1–203.CrossRefPubMedGoogle Scholar
  6. 6.
    Wadden TA, Butryn ML, Hong PS, Wadden TA. Behavioral treatment of obesity in patients encountered in primary care settings: a systematic review. JAMA. 2014;312:1779–91.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Antognoli EL, Seeholzer EL, Gullett H. Primary care resident training for obesity, nutrition, and physical activity counseling. Health Promot Pract. 2017;18(5):672–80.CrossRefPubMedGoogle Scholar
  8. 8.
    Gudzune KA, Beach MC, Roter DL. Physicians build less rapport with obese patients. Obesity (Silver Spring). 2013;21(10):2146–52.CrossRefGoogle Scholar
  9. 9.
    Jensen MD, Ryan DH, Donato KA, Apovian CM, Ard JD, Comuzzie AG, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ. Guidelines (2013) for managing overweight and obesity in adults. Obesity. 2014;22(S2):S1–S410.CrossRefGoogle Scholar
  10. 10.
    National Institute for Health and Care Excellence (UK). National Institute for Health and Clinical Excellence: guidance. Obesity: identification, assessment and management of overweight and obesity in children, young people and adults: partial update of CG43. National Clinical Guideline Centre (UK). 2014.Google Scholar
  11. 11.
    Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring). 2014;22(1):5–13.CrossRefGoogle Scholar
  12. 12.
    Bray GA, Frühbeck G, Ryan DH. Management of obesity. Lancet. 387(10031):1947–56.Google Scholar
  13. 13.
    Unick JL, Neiberg RH, Hogan PE. Weight change in the fi rst 2 months of a lifestyle intervention predicts weight changes 8 years later. Obesity (Silver Spring). 2015;23:1353–6.CrossRefGoogle Scholar
  14. 14.
    Watson S, Woodside JV, Ware LJ. Effect of a web-based behavior change program on weight loss and cardiovascular risk factors in overweight and obese adults at high risk of developing cardiovascular disease: randomized controlled trial. J Med Internet Res. 2015;17(7):e177.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Stuart R. Behavioral control of overeating. Behav Ther. 1967;5:357–65.CrossRefGoogle Scholar
  16. 16.
    Association ACoCH. Task force on Practice Guidelines, Obesity Expert Panel, 2013. Expert panel report: guidelines (2013) for the management of overweight and obesity in adults. Obesity (Silver Spring). 2014;22(Suppl 2):S41–410.Google Scholar
  17. 17.
    Baker RC, Kirschenbaum D. Self-monitoring may be necessary for successful weight control. Behav Ther. 1993;24(3):377–94.CrossRefGoogle Scholar
  18. 18.
    Klem ML, Wing RR, MT MG. A descriptive study of individuals successful at long-term maintenance of substantial weight loss. Am J Clin Nutr. 1977;66(2):239–46.CrossRefGoogle Scholar
  19. 19.
    Mc Guire M, Wing RR, Klem ML. Behavioral strategies of individuals who have maintained long-term weight losses. Obes Res. 1999;7(4):334–41.CrossRefGoogle Scholar
  20. 20.
    Steinberg D, Tate D, Bennett G. The efficacy of a daily self-weogjomg weight loss intervention using smart scales and e-mail. Obesity (Silver Spring). 2013;21(9):1789–97.Google Scholar
  21. 21.
    Knowler WC, Barrett-Connor E, Fowler SE. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.CrossRefPubMedGoogle Scholar
  22. 22.
    Knowler WC, Fowler SE, Hamman RF. Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677–86.CrossRefPubMedGoogle Scholar
  23. 23.
    Wadden TA, Berkowitz RI, Womble LG. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353(20):2111–21120.CrossRefPubMedGoogle Scholar
  24. 24.
    Wing RR, Tate D, Gorin A. A self-regulation program for maintenance of weight loss. N Engl J Med. 2006;355(15):1563–71.CrossRefPubMedGoogle Scholar
  25. 25.
    Brownell KD. The LEARN program for weight management. Dallas: American Health Publishing Company; 2004. ISBN-10: 1878513419; ISBN-13: 978-1878513410Google Scholar
  26. 26.
    Alamuddin N, Wadden TA. Behavioral treatment of the patient with obesity. Endocrinol Metab Clin N Am. 2016;45(3):565–80.CrossRefGoogle Scholar
  27. 27.
    Kokkinos A, le Roux CW, Alexiadou K. Eating slowly increases the postprandial response of the anorexigenic gut hormones, peptide YY and glucagon-like peptide-1. J Clin Endocrinol Metab. 2010;95(1):333–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Avenell A Broom J, Brown TJ. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess. 2004;8(21):III–V.PubMedGoogle Scholar
  29. 29.
    Foreyt JP, Johnston C. Behavior modification and cognitive therapy. In: Mechanick J, editor. Lifestyle medicine a manual for clinical practice. Cham: Springer International Publishing; 2016. Chapter 14, p. 129–34.Google Scholar
  30. 30.
    Perri MG, Limacher MC, Durning PE. Extended-care programs for weight management in rural communities: the treatment of obesity in undeserved rural settings (TOURS) randomized trial. Arch Intern Med. 2008;168(21):2347–54.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Heymsfield SB, Wadden T. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376(3):254–66.CrossRefPubMedGoogle Scholar
  32. 32.
    Ryan D, Heaner M. Guidelines (2013) for managing overweight and obesity in adults. Obesity. 2014;22(suppl 2):S1–3.CrossRefPubMedGoogle Scholar
  33. 33.
    Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med. 1995;332(10):621–8.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Das SK, Gilhooly CH, Golden JK. Long-term effects of 2 energy-restricted diets differing in glycemic load on dietary adherence, body composition, and metabolism in CALERIE: a 1-y randomized controlled trial. Am J Clin Nutr. 2007;85(4):1023–30.CrossRefPubMedGoogle Scholar
  35. 35.
    Johnston BC, Kanters S, Bandayrel K. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA. 2014;312(9):923–33.CrossRefPubMedGoogle Scholar
  36. 36.
    Apovian CM, Aronne LJ, Bessesen DH. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–62.CrossRefPubMedGoogle Scholar
  37. 37.
    Stegenga H, Haines A, Jones K, Wilding J. Identification, assessment, and management of overweight and obesity: summary of updated NICE guidance. BMJ. 2014;349:g6608.  https://doi.org/10.1136/bmj.g6608.CrossRefPubMedGoogle Scholar
  38. 38.
    Logue J, Thompson L, Romanes F. Scottish Intercollegiate Guidelines Network. Guidelines: management of obesity: summary of SIGN guideline. BMJ. 2010;340.; 7744(27):474–7.Google Scholar
  39. 39.
    Tsai AG, Wadden TA. The evolution of very-low-calorie diets: an update and meta-analysis. Obesity (Silver Spring). 2006;14(8):1283–93.CrossRefGoogle Scholar
  40. 40.
    Westman EC, Feinman RD, Mavropoulos JC. Low-carbohydrate nutrition and metabolism. Am J Clin Nutr. 2007;86:276–84.CrossRefPubMedGoogle Scholar
  41. 41.
    Tobias DK, Chen M, Manson JE, Ludwig DS, Willett W, Hu FB. Effect of low-fat diet in-terventions versus other diet interventions on long-term weight change in adults: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3(12):968–79.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Hall K. Prescribing low-fat diets: useless for long-term weight loss? Lancet Diabetes Endocrinol 2015; Published Online S2213-8587 (15) 00413-1.Google Scholar
  43. 43.
    Ludwig DS, Friedman MI. Increasing adiposity: consequence or cause of overeating? JAMA. 2014;311(21):2167–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Hall K, Bemis T, Brychta R. Calorie for calorie, dietary fat restriction results in more body fat loss than carbohydrate restriction in people with obesity. Cell Metab. 2015;22(3):427–36.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Hession M, Rolland C, Kulkarni U. Systematic review of randomized controlled trials of low-carbohydrate vs. low-fat/low-calorie diets in the management of obesity and its comorbidities. Obes Rev. 2009;10(1):36–50.CrossRefPubMedGoogle Scholar
  46. 46.
    Franz MJ, VanWormer JJ, Crain AL. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107(10):1755–67.CrossRefPubMedGoogle Scholar
  47. 47.
    Hall KD, Sacks G, Chandramohan D. Quantification of the effect of energy imbalance on bodyweight. Lancet. 2011;378(9793):826–37.CrossRefPubMedGoogle Scholar
  48. 48.
    Sanghvi A, Redman LM, Martin CK. Validation of an inexpensive and accurate mathematical method to measure long-term changes in free-living energy intake. Am J Clin Nutr. 2015;102(2):353–8.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    MacLean PS, Wing RR, Davidson T. NIH working group report: innovative research to improve maintenance of weight loss. Obesity (Silver Spring). 2015;23(1):7–15.CrossRefGoogle Scholar
  50. 50.
    Sumithran P, Prendergast LA, Delbridge E. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597–604.CrossRefPubMedGoogle Scholar
  51. 51.
    National Institute for Health and Clinical Excellence: Guidance. Obesity: identification, assessment and management of overweight and obesity in children, young people and adults. London: National Clinical Guideline Centre (UK). National Institute for Health and Care Excellence (UK); 2014. nice.org.uk/guidance/cg189.
  52. 52.
    Ross R, Hudson R, Stotz PJ. Effects of exercise amount and intensity on abdominal obesity and glucose tolerance in obese adults: a randomized trial. Ann Intern Med. 2015;162(5):325–34.CrossRefPubMedGoogle Scholar
  53. 53.
    National Institute for Health and Clinical Excellence (NICE). Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. London: NICE; 2006. Available from url: http://guidance.nice.org.uk/CG43.Google Scholar
  54. 54.
    Slentz CA, Duscha BD, Johnson JL. Effects of the amount of exercise on body weight, body composition, and measures of central obesity: STRRIDE–a randomized controlled study. Arch Intern Med. 2004;164(1):31–9.CrossRefPubMedGoogle Scholar
  55. 55.
    Hinkle W, Cordell M, Leibel R. Effects of reduced weight maintenance and leptin repletion on functional connectivity of the hypothalamus in obese humans. PLoS One. 2013;8:e5914.CrossRefGoogle Scholar
  56. 56.
    Rosembaum M, Hirsch J, Gallagher DA. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Am J Clin Nutr. 2008;88(4):906–12.CrossRefGoogle Scholar
  57. 57.
    Pucci A, Finer N. New medications for treatment of obesity: metabolic and cardiovascular effects. Can J Cardiol. 2015;31(2):142–52.CrossRefPubMedGoogle Scholar
  58. 58.
    Nuffer W, Trujillo JM, Megyeri JA. Comparison of new pharmacological agents for the treatment of obesity. Ann Pharmacother. 2016;50(5):376–88.CrossRefPubMedGoogle Scholar
  59. 59.
    Weintraub M, Sundaresan PR, Madan M. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin Pharmacol Ther. 1992;51(5):595–601.CrossRefPubMedGoogle Scholar
  60. 60.
    Sjöström L, Rissanen A, Andersen T. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352(9123):167–72.CrossRefPubMedGoogle Scholar
  61. 61.
    Chanoine JP, Hampl S, Jensen C. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005;293(23):2873–83.CrossRefPubMedGoogle Scholar
  62. 62.
    Torgerson JS, Hauptman J, Boldrin MN. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–61.CrossRefPubMedGoogle Scholar
  63. 63.
    Smith SR, Weissman NJ, Anderson CM. Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–56.CrossRefPubMedGoogle Scholar
  64. 64.
    Fidler MC, Sanchez M, Raether B, for the BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067–77.CrossRefPubMedGoogle Scholar
  65. 65.
    Aronne LJ, Wadden TA, Peterson C. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013;21(11):2163–71.CrossRefGoogle Scholar
  66. 66.
    Allison DB, Gadde KM, Garvey WT. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2010;20(2):330–42.CrossRefGoogle Scholar
  67. 67.
    Apovian CM, Aronne L, Rubino D, COR-II Study Group. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935–43.CrossRefGoogle Scholar
  68. 68.
    Wadden TA, Foreyt JP, Foster GD. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110–20.CrossRefGoogle Scholar
  69. 69.
    Astrup A, Carraro R, Finer N. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36(6):843–54.CrossRefGoogle Scholar
  70. 70.
    Gadde KM, Allison DB, Ryan DH. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–52.CrossRefPubMedGoogle Scholar
  71. 71.
    Crane J, McGowan B. The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. Ther Adv Chronic Dis. 2016;7(2):92–107.CrossRefPubMedGoogle Scholar
  72. 72.
    Rueda-Clausen CF, Padwal RS, Sharma AM. New pharmacological approaches for obesity management. Nat Rev Endocrinol. 2013;9:467–78.CrossRefPubMedGoogle Scholar
  73. 73.
    Giddens JM, Sheehan KH, Sheehan DV. The Columbia suicidality severity rating scale (C-SSRS): has the gold standard become a liability? Innov Clin Neurosci. 2014;11(9–10):66–80.PubMedPubMedCentralGoogle Scholar
  74. 74.
    Khera R, Murad MH, Chandar AK. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315(22):2424.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Chang SH, Stoll CR, Song J. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis 2003–2012. JAMA Surg. 2014;149(3):275–87.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Schauer PR, Bhatt DL, Kirwan JP for the STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes – 5-year outcomes. N Engl J Med. 2017;376(7):641–51.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Arterburn DE, Weidenbacher H, Maciejewski ML. Association between bariatric surgery and long-term survival. JAMA. 2015;313(1):62–70.CrossRefPubMedGoogle Scholar
  78. 78.
    Wang BC, Furnback W. Modelling the long-term outcomes of bariatric surgery: a review of cost-effectiveness studies. Best Pract Res Clin Gastroenterol. 2013;27(6):987–95.CrossRefPubMedGoogle Scholar
  79. 79.
    Mechanick J, Youdim A, Jones DB. AACE/TOS/ASMBS guidelines clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring). 2013;21(0 1):S1–27.CrossRefGoogle Scholar
  80. 80.
    Mc Kinney L, Skolnik N, Chrusch A. Diagnosis and management of obesity. American Academy of Family Physicians. 2013. http://www.aafp.org/dam/AAFP/documents/patient_care/fitness/obesity-diagnosis-management.pdf.
  81. 81.
    Nguyen NT, Masoomi H, Magno CP. Trends in use of bariatric surgery 2003–2008. J Am Coll Surg. 2011;213(2):261–6.CrossRefPubMedGoogle Scholar
  82. 82.
    Funk LM, Jolles SA, Greenberg CC. Primary care physician decision making regarding severe obesity and bariatric surgery: a qualitative study. Surg Obes Relat Dis. 2016;12(4):893–901.CrossRefPubMedGoogle Scholar
  83. 83.
    Pi-Sunyer FX, Aronne LJ, et al. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. Bethesda: National Heart, Lung, and Blood Institute; 2000.Google Scholar
  84. 84.
    Daniel S, Soleymani T, Garvey WT. A complications-based clinical staging of obesity to guide treatment modality and intensity. Curr Opin Endocrinol Diabetes Obes. 2013;20(5):377–88.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obes (Lond). 2009;33(3):289–95.CrossRefGoogle Scholar
  86. 86.
    Garvey WT. New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approach. Endocr Pract. 2013;19(5):864–74.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Beamish AJ, Olbers T, Kelly AS, Inge TI. Cardiovascular effects of bariatric surgery. Nat Rev Cardiol. 2016;13:730–43.  https://doi.org/10.1038/nrcardio.2016.162.CrossRefPubMedGoogle Scholar
  88. 88.
    Santini F, Busetto L, Cresci B, Sbraccia P. SIO management algorithm for patients with overweight or obesity: consensus statement of the Italian Society for Obesity (SIO). Eat Weight Disord. 2016;21:305–7.  https://doi.org/10.1007/s40519-016-0279-3.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Dixon JB, Zimmet P, Alberti KG. International Diabetes Federation Taskforce on Epidemiology and Prevention. Bariatric surgery: an IDF statement for obese type 2 diabetes. Diabet Med. 2011;28(6):628–42.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Handelsman Y, Bloomgarden ZT, Grunberger G. American Association of Clinical Endocrinologists and American College of Endocrinology – clinical practice guidelines for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2015;21(Suppl 1):1–87.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    American Diabetes Association. Standards of medical care in diabetes 2017. Diabetes Care. 2017;40(Supp 1):S11.CrossRefGoogle Scholar
  92. 92.
    Guo F, Moellering DR, Garvey WT. The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity. Obesity. 2014;22(1):110–8.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Marianela Aguirre Ackermann
    • 1
  1. 1.Obesity and Diabetes DepartmentCentro CIEN - Endocrinology, Obesity and Nutrition Center, Corrientes, Buenos Aires, MisionesFormosaArgentina

Personalised recommendations